Roundtable on Black in cancer research and oncology - presented by Dr. Brandon Blue MD and Dr. Kilan Ashad-Bishop and Drs. Onyinye and Folu Balogun and Runcie C.W. Chidebe Dip., BSc., MSc., and Kathryn Mcginnis and Dr Paraskevi Mallini and Dr. Lisa Hoffmann-Haas

Roundtable on Black in cancer research and oncology

Brandon Blue, Kilan Ashad-Bishop, Onyinye and Folu Balogun and Runcie C.W. Chidebe

Dr. Brandon Blue MDDr. Kilan Ashad-BishopDrs. Onyinye and Folu BalogunRuncie C.W. Chidebe Dip., BSc., MSc.,
Slide at 26:37
The Onc Docs Dr. On Polyethnic-1000 Phase 2. Endometrium Mechanisms of Endometrial Cancer Disparities in African Americans Whole-genome and transcriptome sequencing of tumors from African-American patients, recruited in Brooklyn, Queens and Long Island. Biorepository and organoid developments for Onyinye Marina Semir further characterization and drug screening. Balogun Frimer Hypotheses related to the frequency of Beyaz PI3K/PTEN and P53 mutations in African- American women with endometrial cancer. Cold NewYork- Presbyterian Spring Brooklyn Methodist Harbor Northwell Hospital Laboratory Health Weill Cornell Medicine NewYork-Presbyterian
Share slide
Summary (AI generated)

And so, this is part of a project called the Poly Ethnic 1000, in which I also have a role as a cancer and inequity scholar. We are funding about seven different projects looking at eight different tumors through the Poly Ethnic 1000. Our focus is on enrolling populations from minority backgrounds to understand the spectrum of bio changes that may lead to cancer inequities.

I am particularly proud of our project because I work at Brooklyn Methodist, a community hospital that is not typically known for this type of research. However, we have created the necessary infrastructure to carry out this project. We recognize that individuals from minority backgrounds often seek treatment at community hospitals rather than academic centers.

Here is our workflow: we obtain informed consent from participants, collect blood and uterine tumor samples during surgery, and send them for DNA and RNA sequencing. Additionally, we aim to grow organoids, which involve taking a piece of the tumor.